Mobile

A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inh...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-019798-13

A Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Patients with Type 2 Diabetes with not very well controlled high blood pressure taking medicine called Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and Medication to reduce high Blood Preassure in addition. The Phase 3 Trial is carried out at several sites and neither patients nor doctors know which study treatment (medication in different strength or dummy treatment) they are assigned to

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To compare the change from baseline in seated systolic blood pressure after 12 weeks of double-blind treatment with dapagliflozin 10 mg treatment group and the placebo treatment group. • To compare the change from baseline in HbA1c after 12 weeks of double-blind treatment with dapagliflozin 10 mg treatment group versus placebo treatment group.

Critère d'inclusion

  • Type 2 diabetes with inadequate glycemic control and inadequately controlled hypertension

Liens